Stryker has now twice defeated Treace's antitrust claims at the pleading stage, significantly reducing the risk of a disruptive bundling challenge. However, patent infringement claims remain pending, and Treace may seek leave to amend again. Monitor for any third amended complaint or summary judgment motions on the patent counts.
Price Chart
Executive Summary
Stryker won dismissal of Treace Medical's antitrust (Sherman Act, Clayton Act, state antitrust) and tortious interference claims without prejudice, marking the second time the court has rejected these counts at the pleading stage. The ruling removes the immediate threat of treble damages and injunctive relief from Stryker's bundling practices, though patent infringement claims remain pending.
Court Ruling Details
Key Facts
- Court granted Stryker's motion to dismiss Counts XIII–XVI (antitrust and tortious interference) without prejudice.
- Antitrust claims dismissed for failure to plead antitrust injury—allegations were conclusory and only showed harm to Treace, not to competition in the TMT bunion systems market.
- Tortious interference claim dismissed because it was based on the same alleged anticompetitive conduct as the antitrust counts.
- This is the second dismissal of these claims; the original complaint was dismissed in October 2025.
- Patent infringement claims (Counts I–XII) remain active and were not addressed in this ruling.
Financial Impact
Dismissal of antitrust and tortious interference claims removes potential treble damages and injunctive relief exposure; patent claims remain pending with unknown damages exposure.
Risk Factors
- Treace may file a second amended complaint with more specific antitrust allegations, potentially reviving the dismissed counts.
- Patent infringement claims (Counts I–XII) remain pending and could result in damages or injunctive relief if Stryker is found to infringe.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-889e1f0a26-SYK |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Press Release | $317.40 $275.39 | ▼ −13.24% | ▼ −13.55% | $275.43 (−13.22%) |
Aug 26, 2026 5w ago | Insider Cluster | $329.67 $274.19 | ▼ −16.83% | ▼ −18.03% | $275.43 (−16.45%) |
Aug 20, 2026 6w ago | Insider Cluster | $327.70 $280.13 | ▼ −14.52% | ▼ −14.52% | $275.43 (−15.95%) |
Jul 13, 2026 11w ago | Court Ruling | $331.45 $345.81 | ▲ +4.33% | ▲ +1.15% | $275.43 (−16.90%) |
Jul 9, 2026 12w ago | ANALYST-UPGRADE | $327.11 $337.43 | ▲ +3.15% | ▲ +0.91% | $275.43 (−15.80%) |
Jun 26, 2026 14w ago | 8-K | $332.71 $318.97 | ▼ −4.13% | ▼ −5.39% | $275.43 (−17.22%) |
Jun 17, 2026 15w ago | Court Ruling | $301.14 $331.20 | ▲ +9.98% | ▲ +8.66% | $275.43 (−8.54%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $275.43 (−7.96%) |
May 29, 2026 17w ago | Insider Cluster | $299.24 $330.52 | ▲ +10.45% | ▲ +12.77% | $275.43 (−7.96%) |
Apr 30, 2026 22w ago | Press Release | $293.78 $299.24 | ▼ −1.86% | ▲ +3.41% | $275.43 (+6.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access